MOLECULAR PARTNERS SF 1
Research MOLECULAR PARTNERS SF 1 (6ML) on Bullrun: market cap EUR 138.79M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6ML
- ExchangeF
- CountrySwitzerland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 138.79M
- Financial periodQ1 2026
- RevenueCHF 0
- Net income-CHF 13.14M
- Free cash flow-CHF 14.24M
Valuation Snapshot
latest market cap is EUR 138.79M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CHF 0 | -CHF 61.65M | -CHF 51.97M | n/a | n/a | CHF 82.65M | CHF 3.64M | CHF 80.33M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 138.79M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About MOLECULAR PARTNERS SF 1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is MOLECULAR PARTNERS SF 1's market cap?
MOLECULAR PARTNERS SF 1's market capitalization is EUR 138.79M.
What does MOLECULAR PARTNERS SF 1 do?
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.